-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Prostate cancer is a malignant tumor that comes from the prostate.
most prostate cancers grow more slowly, but some still grow relatively quickly.
cancer cells can be transferred to areas such as bones and lymph nodes.
may be asymptomatic in the early stages of prostate cancer, which can lead to difficulty urinating, blood urine, back pain, pelvic pain and other symptoms.
the U.S. Food and Drug Administration (FDA) recently said it has approved Myovant Sciences' GnRH-subject antagonist Orgovyx (relugolix) to treat patients with advanced prostate cancer.
approval was supported by the HERO trial, which treated more than 900 patients with androgen-sensitive advanced prostate cancer for at least a year for ongoing androgen deprivation.
patients were randomly treated once a day with Orgovyx or the hormone-targeted drug lysolin.
results showed that Orgovyx reached the primary therapeutic endpoint, with 96.7 percent of patients receiving treatment achieving continuous testosterone suppression at levels below 50 ng/ dL, while 88.8 percent of patients treated had a deseed level of less than 50 ng / dL.
, however, the results showed that the drug could not significantly improve the survival rate of patients with desopathic resistance compared to litaquine.
。
